Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Decapinol™ rinse is a new product indicated for the treatment of gingivitis and prevention of periodontitis.

Sinclair Pharmaceuticals
Decapinol

Mechanism of action

Decapinol changes the surface properties of the salivary layer coating the teeth, so bacteria cannot easily adhere and colonise

Full description

DecapinolTM rinse contains a cationic surfactant Delmopinol Hydrochloride 2mg/ml; Decapinol rinse has a unique mode of action, which prevents the attachment as well as the adherence of plaque bacteria to the teeth, gingiva and to itself. This interference with the plaque build-up process prevents the onset of gingivitis that can lead to periodontitis.

It also interferes with the enzyme GTF, which is responsible for the production of glucans (the glue or cement that is critical for plaque build-up). This results is less cohesive and less adhesive plaque bacteria, making it easier to remove by conventional tooth brushing techniques.

It also maintains a healthy composition of oral bacteria .

Decapinol is presented as a flavoured mouthwash. It contains Delmopinol hydrochloride 2mg/ml, saccharin sodium, anhydrous ethanol, herb flavour (aniseed, eucalyptus, mint), sodium hydroxide and purified water.

It is available in the following presentations: 300ml, 200ml, 120ml and sample sizes 40ml and 10ml sachets.

Delmopinol Hydrochloride helps to treat and prevent gingivitis and periodontitis, and reduce periodontal pocket depth through its application along the gingival margin and into interdental spaces.

Its key ingredient is the cationic surfactant Delmopinol hydrochloride (5mg/ml) and its unique mode of action prevents the attachment as well as the adherence of plaque bacteria to the teeth, gingiva and to itself . This interference with the plaque build-up process prevents the onset of gingivitis that can lead to periodontitis.

It also interferes with the enzyme GTF, which is responsible for the production of glucans (the glue or cement that is critical for plaque build-up). This results is less cohesive and less adhesive plaque bacteria, making it easier to remove by conventional tooth brushing techniques.

It also maintains a healthy composition of oral bacteria .

Decapinol rinse is presented as a flavoured mouthwash. It contains Delmopinol hydrochloride 2mg/ml, saccharin sodium, anhydrous ethanol, herb flavour (aniseed, eucalyptus, mint), sodium hydroxide and purified water.

It is available in the following presentations: 300ml, 200ml, 120ml and sample sizes 40ml and 10ml sachets.

Disease overview

Gingivitis is a non-specific term used to describe an inflammation of the gums (gingiva), regardless of the ætiology, and affects approximately 80-90% of the adult population . Plaque-associated gingivitis is an inflammation of the interdental and gingival margin that can be controlled or prevented by removing and/or inhibiting microbial plaque accumulation.

Periodontitis is a more serious condition, involving inflammation of the periodontium, the areas surrounding the teeth - this usually affects 13%-15% of the adult population . The structures that anchor the teeth to the bone are affected - there may be apical migration of epithelial attachment and loss of alveolar bone leading to tooth and bone loss.

Gingivitis always precedes periodontitis and so prevention or treatment of gingivitis is considered an accepted method of preventing periodontitis

Stage of development

In the European Union, Decapinol Rinse is registered as a Class IIa medical device, and has as such been awarded a CE mark. The Medical Device Directive applies to all European Union countries, which means Decapinol Rinse can be sold freely within these countries, without further registration requirements. The CE mark signifies the product's conformity with the Directive.

In the United States, Decapinol Rinse has been approved by the FDA, and classified as a Class II Medical Device, as a prescription only product.

 

Development status

Registered

Patent information

Patents pending - Please refer to Sinclair's Business Development team for an update on Decapinol IP situation.

 

 

Type of business relationship sought

Marketing companies are required to sell Decapinol in key territories around the world.

Licensing contact

Javier Boza
Global Business Development Director
Request more information

More information

For more information about the product please visit website.

Company details

Sinclair Pharmaceuticals
Sinclair Pharma plc, a rapidly growing UK based pharmaceutical company is seeking distributors around the world.

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Partnering consultation free of charge
Biomarkers for sepsis and infectious diseases
MipTec
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us